Literature DB >> 18356312

Health technology assessment in the cost-disutility plane.

Simon Eckermann1, Andrew Briggs, Andrew R Willan.   

Abstract

Previously, comparisons of multiple strategies in health technology assessment have been undertaken on the incremental cost-effectiveness plane using efficiency frontiers and cost-effectiveness acceptability curves. This article proposes shifting the comparison of multiple strategies to the cost-disutility plane. Evidence-based decision making requires comparison of all strategies against each other. Consequently, the origin in the incremental cost-effectiveness plane cannot be the appropriate reference point in comparing multiple nondominated strategies. A linear transformation onto the cost-disutility plane allows an equivalent comparison of net benefit and permits the use of standard efficiency measurement methods to estimate 1) the degree of dominance (technical inefficiency) of dominated strategies and 2) the net benefit inefficiency (i.e., losses in net benefit relative to an optimal strategy). In comparing strategies under uncertainty, a comparison of loss in net benefit leads to the expected net loss frontier, which, unlike cost effectiveness acceptability curves, directly identifies differences in expected net benefit (net loss) and the expected value of perfect information. Thus, decision makers can be better informed about the choice of optimal strategy and the potential value of future research to resolve uncertainty. Comparing strategies in the cost-disutility plane is suggested to better inform decision making and to provide a link between the cost-effectiveness literature and efficiency measurement methods.

Mesh:

Year:  2008        PMID: 18356312     DOI: 10.1177/0272989X07312474

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  10 in total

1.  The value of value of information: best informing research design and prioritization using current methods.

Authors:  Simon Eckermann; Jon Karnon; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Consistently estimating absolute risk difference when translating evidence to jurisdictions of interest.

Authors:  Simon Eckermann; Michael Coory; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

3.  Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.

Authors:  Louisa G Gordon; Nicholas G Hirst; George C Mayne; David I Watson; Timothy Bright; Wang Cai; Andrew P Barbour; Bernard M Smithers; David C Whiteman; Simon Eckermann
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

4.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

5.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

Review 6.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

7.  Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.

Authors:  Nikki McCaffrey; Meera Agar; Janeane Harlum; Jonathon Karnon; David Currow; Simon Eckermann
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

8.  Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice.

Authors:  Joke Bilcke; Philippe Beutels
Journal:  Med Decis Making       Date:  2021-10-15       Impact factor: 2.583

9.  Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.

Authors:  Henri B Wolff; Venetia Qendri; Natalia Kunst; Fernando Alarid-Escudero; Veerle M H Coupé
Journal:  Med Decis Making       Date:  2022-05-19       Impact factor: 2.749

10.  Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.

Authors:  Lieven Annemans; Mélanie Brignone; Sylvain Druais; Ann De Pauw; Aline Gauthier; Koen Demyttenaere
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.